Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | RB1 del |
| Gene Variant Detail | |
| Relevant Treatment Approaches | HDAC Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| RB1 del | prostate cancer | sensitive | JQ1 | Preclinical | Actionable | In a preclinical study, JQ1 treatment inhibited tumor growth in a syngeneic mouse model of RB1-deficient prostate cancer (PMID: 37014264). | 37014264 | |
| RB1 del | prostate cancer | sensitive | JQ1 + unspecified PD-L1 antibody | Preclinical | Actionable | In a preclinical study, the combination of JQ1 and an anti-PD-L1 therapy inhibited tumor growth in a syngeneic mouse model of RB1-deficient prostate cancer (PMID: 37014264). | 37014264 | |
| RB1 del | prostate adenocarcinoma | sensitive | Decitabine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Dacogen (decitabine) inhibited viability of castration-resistant prostate adenocarcinoma cells with loss of RB1 via knockout in culture and inhibited tumor growth in cell line xenograft models (PMID: 37967200). | 37967200 | |
| RB1 del | Her2-receptor negative breast cancer | predicted - sensitive | REC-617 | Preclinical - Cell culture | Actionable | In a preclinical study, REC-617 (GTAEXS617) induced cell cycle arrest and apoptosis in CDK4/6 inhibitor-resistant, ESR1-positive, ERBB2 (HER2)-negative breast cancer cells with Rb deletion (Cancer Res (2025) 85 (8_Supplement_1): 366). | detail... |